The results demonstrated that acquired ERBB2/ERBB3 mutations by tumor cells are essential to induce checkpoint PD-L1, rendering tumor cells evasive from cytotoxic T cell immunity against tumor. The gene discussed is ERBB2; the disease is neoplasm.